Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

379 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile.
Sannier G, Nicolas A, Dubé M, Marchitto L, Nayrac M, Tastet O, Chatterjee D, Tauzin A, Lima-Barbosa R, Laporte M, Cloutier R, Sreng Flores AM, Boutin M, Gong SY, Benlarbi M, Ding S, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Brassard N, Delgado GG, Niessl J, Gokool L, Morrisseau C, Arlotto P, Rios N, Tremblay C, Martel-Laferrière V, Prat A, Bélair J, Beaubien-Souligny W, Goupil R, Nadeau-Fredette AC, Lamarche C, Finzi A, Suri RS, Kaufmann DE. Sannier G, et al. Among authors: laporte m. Cell Rep Med. 2023 Mar 21;4(3):100955. doi: 10.1016/j.xcrm.2023.100955. Epub 2023 Feb 7. Cell Rep Med. 2023. PMID: 36863335 Free PMC article.
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen.
Nayrac M, Dubé M, Sannier G, Nicolas A, Marchitto L, Tastet O, Tauzin A, Brassard N, Beaudoin-Bussières G, Vézina D, Gong SY, Benlarbi M, Gasser R, Laumaea A, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Ortega-Delgado GG, Laporte M, Niessl J, Gokool L, Morrisseau C, Arlotto P, Richard J, Tremblay C, Martel-Laferrière V, Finzi A, Kaufmann DE. Nayrac M, et al. Among authors: laporte m. bioRxiv [Preprint]. 2021 Dec 21:2021.12.18.473317. doi: 10.1101/2021.12.18.473317. bioRxiv. 2021. Update in: Cell Rep. 2022 Jun 28;39(13):111013. doi: 10.1016/j.celrep.2022.111013 PMID: 34981046 Free PMC article. Updated. Preprint.
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen.
Nayrac M, Dubé M, Sannier G, Nicolas A, Marchitto L, Tastet O, Tauzin A, Brassard N, Lima-Barbosa R, Beaudoin-Bussières G, Vézina D, Gong SY, Benlarbi M, Gasser R, Laumaea A, Prévost J, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Ortega-Delgado GG, Laporte M, Niessl J, Gokool L, Morrisseau C, Arlotto P, Richard J, Bélair J, Prat A, Tremblay C, Martel-Laferrière V, Finzi A, Kaufmann DE. Nayrac M, et al. Among authors: laporte m. Cell Rep. 2022 Jun 28;39(13):111013. doi: 10.1016/j.celrep.2022.111013. Epub 2022 Jun 13. Cell Rep. 2022. PMID: 35732172 Free PMC article.
An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells.
Nicolas A, Sannier G, Dubé M, Nayrac M, Tauzin A, Painter MM, Goel RR, Laporte M, Gendron-Lepage G, Medjahed H, Williams JC, Brassard N, Niessl J, Gokool L, Morrisseau C, Arlotto P, Tremblay C, Martel-Laferrière V, Finzi A, Greenplate AR, Wherry EJ, Kaufmann DE. Nicolas A, et al. Among authors: laporte m. iScience. 2023 Jan 20;26(1):105904. doi: 10.1016/j.isci.2022.105904. Epub 2022 Dec 29. iScience. 2023. PMID: 36594081 Free PMC article.
Enhanced detection of antigen-specific T cells by a multiplexed AIM assay.
Lemieux A, Sannier G, Nicolas A, Nayrac M, Delgado GG, Cloutier R, Brassard N, Laporte M, Duchesne M, Sreng Flores AM, Finzi A, Tastet O, Dubé M, Kaufmann DE. Lemieux A, et al. Among authors: laporte m. Cell Rep Methods. 2024 Jan 22;4(1):100690. doi: 10.1016/j.crmeth.2023.100690. Epub 2024 Jan 15. Cell Rep Methods. 2024. PMID: 38228152 Free PMC article.
Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R, Jain J, Susan-Resiga D, Andréo U, Evagelidis A, Derbali RM, Huynh DN, Dallaire F, Laporte M, Delpal A, Sutto-Ortiz P, Coutard B, Mapa C, Wilcoxen K, Decroly E, Nq Pham T, Cohen ÉA, Seidah NG. Essalmani R, et al. Among authors: laporte m. J Virol. 2022 Apr 27;96(8):e0012822. doi: 10.1128/jvi.00128-22. Epub 2022 Mar 28. J Virol. 2022. PMID: 35343766 Free PMC article.
Erratum for Essalmani et al., "Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity".
Essalmani R, Jain J, Susan-Resiga D, Andréo U, Evagelidis A, Derbali RM, Huynh DN, Dallaire F, Laporte M, Delpal A, Sutto-Ortiz P, Coutard B, Mapa C, Wilcoxen K, Decroly E, Pham TNQ, Cohen ÉA, Seidah NG. Essalmani R, et al. Among authors: laporte m. J Virol. 2022 Jul 13;96(13):e0074522. doi: 10.1128/jvi.00745-22. Epub 2022 Jun 6. J Virol. 2022. PMID: 35658532 Free PMC article. No abstract available.
Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance.
Bridges K, Pizzurro GA, Baysoy A, Baskaran JP, Xu Z, Mathew V, Tripple V, LaPorte M, Park K, Damsky W, Kluger H, Fan R, Kaech SM, Bosenberg MW, Miller-Jensen K. Bridges K, et al. Among authors: laporte m. bioRxiv [Preprint]. 2024 Oct 31:2024.10.28.620093. doi: 10.1101/2024.10.28.620093. bioRxiv. 2024. PMID: 39554094 Free PMC article. Preprint.
379 results